Targeted Therapy Combinations Provide Multiple Treatment Options in BRAF-Mutated Melanoma
Source: Onc Live, October 2022
Jeff Yorio, MD, discussed the decision-making process for treating patients with BRAF-mutant melanoma, the use of immunotherapy in melanoma, and the management of cutaneous squamous cell carcinoma and basal cell carcinoma.
Various combinations of targeted therapies have generated favorable response rates in patients with BRAF-mutated melanoma, according to Jeff Yorio, MD, who added that investigators are exploring the addition of immunotherapy to these targeted therapy combinations.
Targeted therapies of interest, specifically for patients with BRAF mutations, include vemurafenib (Zelboraf) and cobimetinib (Cotellic), dabrafenib (Tafinlar) and trametinib (Mekinist), and binimetinib (Mektovi) and encorafenib (Braftovi). These combinations, along with patients’ long-term responses are continuing to be evaluated.